Therapeutic Efficacy of SQ641-NE against Mycobacterium tuberculosis | Zendy

B. V. Nikonenko | Zendy; Venkata M. Reddy | Zendy; Elena Bogatcheva | Zendy; Marina Protopopova | Zendy; Leo Einck | Zendy; Carol A. Nacy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Therapeutic Efficacy of SQ641-NE against Mycobacterium tuberculosis

Author(s) -

B. V. Nikonenko,

Venkata M. Reddy,

Elena Bogatcheva,

Marina Protopopova,

Leo Einck,

Carol A. Nacy

Publication year - 2013

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01254-13

Subject(s) - spleen , mycobacterium tuberculosis , clearance , tuberculosis , microbiology and biotechnology , mycobacterium , lung , medicine , intracellular , pharmacology , immunology , chemistry , biology , pathology , biochemistry , urology

A phospholipid-based nanoemulsion formulation of SQ641 (SQ641-NE) was active against intracellularMycobacterium tuberculosis in J774A.1 mouse macrophages, although SQ641 by itself was not. Intravenous (i.v.) SQ641-NE was cleared from circulation and reached peak concentrations in lung and spleen in 1 h. In a murine tuberculosis (TB) model, 8 i.v. doses of SQ641-NE at 100 mg/kg of body weight over 4 weeks caused a 1.73 log10 CFU reduction ofM. tuberculosis in spleen and were generally bacteriostatic in lungs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research